Drug-eluting bead trans-arterial chemoembolization combined with microwave ablation therapy vs. microwave ablation alone for early stage hepatocellular carcinoma: a preliminary investigation of clinical value

Liu, Juanfang; Zhang, Wenguang; Lü, Hao; Li, Hongbin; Zhou, Xueliang; Li, Jing; Han, Xinwei

doi:10.1007/s00432-021-03760-x

Cited by 7 publications

(7 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar effectiveness has already been shown and recommended in liver cancers treated with TACE and thermal ablation (18,19). Liu et al (20) indicate that combined treatment with DEB-TACE has advantages in improving the prognosis of early-stage liver cancer compared to MWA alone. However, few studies have focused on the outcomes of MWA combined with DEB-BACE for ASTRI-NSCLC.…”

Section: Introductionmentioning

confidence: 53%

“…It has been reported that thermal ablation combined with TACE can decrease the recurrence rate and may improve the prognosis compared to ablation monotherapy for early-stage liver cancer ( 18 , 19 ). Identical results were demonstrated in the combination therapy of DEB-TACE and MWA compared to MWA monotherapy for early-stage liver cancer ( 20 ). A study from China reviewed 138 advanced NSCLC patients and found that the 1-, 2-, and 3-year survival rates of the combination therapy group (BACE and radiofrequency ablation) were 90.7%, 58.1%, and 20.9%, respectively, which revealed a better prognosis than that of BACE or ablation monotherapy groups ( 41 ).…”

Section: Discussionmentioning

confidence: 89%

“…Liu et al. ( 20 ) indicate that combined treatment with DEB-TACE has advantages in improving the prognosis of early-stage liver cancer compared to MWA alone. However, few studies have focused on the outcomes of MWA combined with DEB-BACE for ASTRI-NSCLC.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Drug-Eluting Bead Bronchial Arterial Chemoembolization With and Without Microwave Ablation for the Treatment of Advanced and Standard Treatment-Refractory/Ineligible Non-Small Cell Lung Cancer: A Comparative Study

Bie

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

PurposeTo compare the outcomes of drug-eluting bead bronchial arterial chemoembolization (DEB-BACE) with and without microwave ablation (MWA) for the treatment of advanced and standard treatment-refractory/ineligible non-small cell lung cancer (ASTRI-NSCLC).Materials and MethodsA total of 77 ASTRI-NSCLC patients who received DEB-BACE combined with MWA (group A; n = 28) or DEB-BACE alone (group B; n = 49) were included. Clinical outcomes were compared between groups A and B. Kaplan–Meier methods were used to compare the median progression-free survival (PFS) or overall survival (OS) between the two groups. Univariate and multivariate Cox proportional hazards analyses were used to investigate the predictors of OS for ASTRI-NSCLC treated with DEB-BACE.ResultsNo severe adverse event was found in both groups. Pneumothorax was the predominant MWA-related complication in group A, with an incidence rate of 32.1% (9/28). Meanwhile, no significant difference was found in DEB-BACE-related complications between groups A and B. The overall disease control rate (DCR) was 61.0% (47/77), with a significantly higher DCR in group A (85.7% vs. 46.9%, P = 0.002). The median PFS in groups A and B was 7.0 and 4.0 months, respectively, with a significant difference (P = 0.037). The median OS in groups A and B was both 8.0 months, with no significant difference (P = 0.318). The 6-month PFS and OS rates in groups A and B were 75.0% and 78.6%, 22.4% and 59.2%, respectively, while the 12-month PFS and OS rates in groups A and B were 17.9% and 28.6%, 14.3% and 22.4%, respectively. Of these, a significantly higher 6-month PFS rate was found in group A (75.0% vs. 22.4%; P < 0.001). The cycles of DEB-BACE/bronchial artery infusion chemotherapy [hazard ratio (HR): 0.363; 95% confidence interval (CI): 0.202–0.655; P = 0.001] and postoperative immunotherapy (HR: 0.219; 95% CI: 0.085–0.561; P = 0.002) were identified as the predictors of OS in ASTRI-NSCLC treated with DEB-BACE.ConclusionMWA sequentially combined with DEB-BACE was superior to DEB-BACE alone in the local control of ASTRI-NSCLC. Although the combination therapy reveals a trend of prolonging the OS, long-term prognosis warrants an investigation with a longer follow-up.

show abstract

Section: Introductionmentioning

confidence: 53%

Section: Discussionmentioning

confidence: 89%

See 1 more Smart Citation

Drug-Eluting Bead Bronchial Arterial Chemoembolization With and Without Microwave Ablation for the Treatment of Advanced and Standard Treatment-Refractory/Ineligible Non-Small Cell Lung Cancer: A Comparative Study

Bie

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…However, the safety data were similar in the two groups [ 27 ]. Patients with HCC treated with DEB-TACE and microwave ablation (MWA) demonstrated higher ORR and DCR when compared with MWA treatment alone [ 28 ]. In the future, we will try to explore the combination in the treatment of liver cancers.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and Safety of Drug-Eluting Bead TACE in the Treatment of Primary or Secondary Liver Cancer

Wang

et al. 2023

Canadian Journal of Gastroenterology and Hepatology

View full text Add to dashboard Cite

Background. The drug-eluting beads transarterial chemoembolization (DEB-TACE) has already been used in hepatic malignancies. We aim to evaluate the efficacy and safety of DEB-TACE in treating primary or secondary liver cancer. Methods. We retrospectively evaluated 59 patients with hepatic malignancies, including 41 patients with primary liver cancer and 18 patients with secondary liver cancer, between September 2016 and February 2019. All patients were treated with DEB-TACE. Objective response rate (ORR) and disease control rate (DCR) were evaluated by mRECIST. The pain was assessed using a numerical rating scale (NRS) where 0 represented no pain, and a score of ten was unbearable. Adverse reactions were assessed according to Common Terminology Criteria for Adverse Events 4.0 (CTCAE4.0). Results. In the subgroup of primary liver cancer, 3 patients (7.32%) got complete response, 13 patients (31.71%) got partial response, 21 patients (51.22%) experienced stable disease, and 4 patients (9.76%) suffered progressive disease; ORR was 39.02% and DCR was 90.24%. In the subgroup of secondary liver cancer, 0 patients (0%) got complete response, 6 patients (33.33%) got partial response, 11 patients (61.11%) experienced stable disease, and 1 patient (5.56%) suffered progressive disease; ORR was 33.33% and DCR was 94.44%. We did not find any difference when comparing the efficacy between primary and secondary liver cancer ( P = 0.612 ). The one-year survival rate was 70.73% for primary liver cancer and 61.11% for secondary liver cancer. There was no significant difference between the two groups ( P = 0.52 ). For the patients with CR or PR, no factor could predict the efficacy of DEB-TACE. The most common treatment-related adverse reactions were short-term liver function disorders. The symptoms included fever (20.34%), abdomen pain (16.95%), and vomiting (5.08%), all patients with adverse reactions got remission after treatment. Conclusions. DEB-TACE has a promising effect in the treatment of primary or secondary liver cancer. The treatment-related adverse reactions are tolerable.

show abstract

“…The results showed that the ECOG score was an independent prognostic factor for OS and PFS of HCC patients after TACE-MWA treatment and was superior to BCLC and mBCLC. [72][73][74] In 2021, Liu et al studied the prognostic prediction value of ECOG score in HCC patients after TACE-cryoablation treatment. The results showed that the ECOG score was an independent prognostic factor for OS and PFS of HCC patients after TACE-cryoablation treatment and was superior to BCLC and mBCLC.…”

Section: Eastern Staging Systemmentioning

confidence: 99%

Evaluation of Multiple Liver Cancer Scoring Systems

Sun,

Qi,

Liu

et al. 2023

Advanced Biology

View full text Add to dashboard Cite

Liver cancer is one of the most common malignant tumors in the world, and its incidence and mortality are increasing year by year. The prognosis of liver cancer depends on the stage of liver cancer, the treatment method, the liver function, and individual differences. The prognosis of liver cancer mainly worsens with the progression of the stage. The prediction and staging system of liver cancer prognosis plays a very important role in the outcome of liver cancer prognosis, providing some guidance for clinical practice and bringing benefits for patients. This article reports on the prediction models and staging systems that have been applied in the field of liver cancer in the past 5 years, objectively analyzes the advantages and disadvantages, applicable population of each model and staging system, and searches for other patient and clinical characteristics that need to be considered for successfully establishing a prediction model, aiming to improve the specificity, sensitivity, and accuracy of liver cancer prediction and increase the overall survival rate of liver cancer.

show abstract

Drug-eluting bead trans-arterial chemoembolization combined with microwave ablation therapy vs. microwave ablation alone for early stage hepatocellular carcinoma: a preliminary investigation of clinical value

Cited by 7 publications

References 22 publications

Drug-Eluting Bead Bronchial Arterial Chemoembolization With and Without Microwave Ablation for the Treatment of Advanced and Standard Treatment-Refractory/Ineligible Non-Small Cell Lung Cancer: A Comparative Study

Drug-Eluting Bead Bronchial Arterial Chemoembolization With and Without Microwave Ablation for the Treatment of Advanced and Standard Treatment-Refractory/Ineligible Non-Small Cell Lung Cancer: A Comparative Study

Efficacy and Safety of Drug-Eluting Bead TACE in the Treatment of Primary or Secondary Liver Cancer

Evaluation of Multiple Liver Cancer Scoring Systems

Contact Info

Product

Resources

About